Recombinant Anti-Flt3 / CD135 (phospho Y589) antibody [EPR2311(2)] (ab171975)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2311(2)] to Flt3 / CD135 (phospho Y589)
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Flt3 / CD135 (phospho Y589) antibody [EPR2311(2)]
See all Flt3 / CD135 primary antibodies -
Description
Rabbit monoclonal [EPR2311(2)] to Flt3 / CD135 (phospho Y589) -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,IHC-P or IP -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Pervanadate treated A431 whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2311(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab171975 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/5000. Detects a band of approximately 130-160 kDa (predicted molecular weight: 112 kDa).
|
Notes |
---|
WB
1/1000 - 1/5000. Detects a band of approximately 130-160 kDa (predicted molecular weight: 112 kDa). |
Target
-
Function
Receptor for the FL cytokine. Has a tyrosine-protein kinase activity. -
Tissue specificity
Bone marrow cells. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 protein kinase domain. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 2322 Human
- Omim: 136351 Human
- SwissProt: P36888 Human
- Unigene: 507590 Human
-
Alternative names
- CD 135 antibody
- CD135 antibody
- CD135 antigen antibody
see all
Images
-
All lanes : Anti-Flt3 / CD135 (phospho Y589) antibody [EPR2311(2)] (ab171975) at 1/1000 dilution
Lane 1 : Untreated A431 (Human epidermoid carcinoma epithelial cell) whole cell lysate
Lane 2 : A431 was starved overnight then treated with 50mM Pervanadate for 5 minutes whole cell lysate
Lane 3 : A431 was starved overnight then treated with 50mM Pervanadate for 5 minutes, then the membrane treated with Alkaline Phosphatase for 1 hour
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 112 kDa
Additional bands at: 130 kDa, 160 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 100 secondsThe molecular weight observed is consistent with literature (PMID: 12406902, PMID: 28895560).
This blot was developed using a higher sensitive ECL substrate.
Blocking/Diluting buffer: 5% NFDM/TBST.
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab171975 has been referenced in 1 publication.
- Kang CW et al. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. Mol Cancer Ther 14:2238-48 (2015). PubMed: 26208525